Ken Griffin Lineage Cell Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 193,968 shares of LCTX stock, worth $368,539. This represents 0.0% of its overall portfolio holdings.

Number of Shares

193,968

Previous 185,481 4.58%

Holding current value

$368,539

Previous $168,000 99.4%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$0.87 - $1.79 $7,383 - $15,191	8,487 Added 4.58%	193,968 $335,000
Q2 2025 Aug 14, 2025	BUY	$0.39 - $1.13 $53,472 - $154,933	137,109 Added 283.45%	185,481 $168,000
Q1 2025 May 15, 2025	SELL	$0.45 - $0.72 $37,531 - $60,050	-83,403 Reduced 63.29%	48,372 $21,000
Q4 2024 Feb 14, 2025	BUY	$0.5 - $0.95 $65,887 - $125,186	131,775 New	131,775 $65,000
Q1 2024 May 15, 2024	SELL	$0.86 - $1.48 $314,939 - $541,989	-366,209 Reduced 62.34%	221,220 $327,000

Q4 2023 Feb 14, 2024	BUY	$0.91 - $1.35 $173,351 - $257,169	190,496 Added 47.99%	587,429 $640,000
Q3 2023 Nov 14, 2023	SELL	$1.16 - $1.53 $7,814 - $10,307	-6,737 Reduced 1.67%	396,933 $468,000
Q2 2023 Aug 14, 2023	BUY	$1.26 - $1.53 $195,350 - $237,211	155,040 Added 62.36%	403,670 $569,000
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $144,472 - $184,202	120,394 Added 93.88%	248,630 $372,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $1.5 $5,548 - $8,160	5,440 Added 4.43%	128,236 $150,000
Q3 2022 Nov 14, 2022	BUY	$1.13 - $1.77 $99,727 - $156,209	88,254 Added 255.5%	122,796 $139,000
Q2 2022 Aug 15, 2022	SELL	$1.12 - $1.61 $24,036 - $34,552	-21,461 Reduced 38.32%	34,542 $55,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.48 $223,839 - $458,777	-184,991 Reduced 76.76%	56,003 $86,000
Q4 2021 Feb 14, 2022	BUY	$1.84 - $2.68 $311,213 - $453,289	169,138 Added 235.38%	240,994 $590,000
Q3 2021 Nov 15, 2021	SELL	$2.26 - $2.86 $5,532 - $7,001	-2,448 Reduced 3.29%	71,856 $181,000
Q2 2021 Aug 16, 2021	SELL	$2.17 - $3.0 $338,333 - $467,742	-155,914 Reduced 67.72%	74,304 $211,000
Q1 2021 May 17, 2021	BUY	$1.77 - $3.1 $382,889 - $670,598	216,322 Added 1556.72%	230,218 $541,000
Q4 2020 Feb 16, 2021	BUY	$0.95 - $1.83 $13,201 - $25,429	13,896 New	13,896 $25,000
Q3 2020 Nov 16, 2020	SELL	$0.75 - $1.09 $85,672 - $124,510	-114,230 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$0.71 - $1.18 $36,418 - $60,525	51,293 Added 81.5%	114,230 $100,000
Q1 2020 May 15, 2020	SELL	$0.6 - $1.58 $19,225 - $50,627	-32,043 Reduced 33.74%	62,937 $52,000
Q4 2019 Feb 14, 2020	BUY	$0.54 - $1.01 $30,018 - $56,144	55,589 Added 141.12%	94,980 $85,000
Q3 2019 Nov 14, 2019	BUY	$0.85 - $1.24 $33,482 - $48,844	39,391 New	39,391 $38,000

Others Institutions Holding LCTX

# of Institutions

128

Shares Held

96M

Call Options Held

251K

Put Options Held

50K

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $323M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account